Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | NPC1 | O15118 | 8/20 | 0.63 |
| ▸ | RAB9A | P51151 | 8/20 | 0.63 |
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222155 | 0.87 | HSP90AA1 (0.68) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL10958445 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL11319860 | 0.84 | RAB9A (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3092283 | 0.84 | RAB9A (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1992777 | 0.84 | RAB9A (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL16697354 | 0.84 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL30996914 | 0.83 | RAB9A (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL1669574 | 0.83 | RAB9A (0.56) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL3618934 | 0.83 | LMNA (0.46) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL11083717 | 0.83 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1NPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016044463-A2 | MK2 INHIBITORS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| WO-2007034251-A1 | AMINO-ALKYL-AMIDE DERIVATIVES AS CCR3 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2007-03-29 | — | — | WO | disclosed |
| US-6800630-B2 | CYTOSTATIC ACTIVITY, INHIBITORY ACTIVITY AGAINST A SIGNAL DERIVED FROM RAS ONCOGENE PRODUCTS | SHIONOGI & CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| EP-1251129-B1 | PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT | SHIONOGI & CO (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-20030203894-A1 | Pyrimidine derivatives having antitumor effect | SHIONOGI & CO., LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1251129-A1 | PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT | SHIONOGI & CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| US-4950648-A | SUBSTITUTED PYRIDO(2,3-D) OR PYRIMIDO(4,5-D) PYRIMIDINE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203894-A1 | Pyrimidine derivatives having antitumor effect | TYMS, TYMP, RRM1 | SMN1; SMN2 4069/4885ALDH1A1 1562/4885NPC1 3114/4885 |
| US-20080293745-A1 | New amino-alkyl-amide derivatives as CCR3 receptor ligands | CCR3, CCR1, CCR4 | SMN1; SMN2 2232/4885ALDH1A1 1778/4885NPC1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.